1
|
Mitchell PD, Salter BM, Oliveria JP, El-Gammal A, Tworek D, Smith SG, Sehmi R, Gauvreau GM, Butler M, O'Byrne PM. Glucagon-like peptide-1 receptor expression on human eosinophils and its regulation of eosinophil activation. Clin Exp Allergy 2017; 47:331-338. [PMID: 27928844 DOI: 10.1111/cea.12860] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2016] [Revised: 10/19/2016] [Accepted: 10/20/2016] [Indexed: 12/17/2022]
Abstract
BACKGROUND Glucagon-like peptide-1 (GLP-1) and its receptor are part of the incretin family of hormones that regulate glucose metabolism. GLP-1 also has immune modulatory roles. OBJECTIVES To measure the expression of the GLP-1 receptor (GLP-1R) on eosinophils and neutrophils in normal and asthmatic subjects and evaluate effects of a GLP-1 analog on eosinophil function. METHODS Peripheral blood samples were taken from 10 normal and 10 allergic asthmatic subjects. GLP-1R expression was measured on eosinophils and neutrophils. Subsequently, the asthmatic subjects underwent allergen and diluent inhalation challenges, and GLP-1R expression was measured. Purified eosinophils, collected from mild asthmatic subjects, were stimulated with lipopolysaccharide (LPS) and a GLP-1 analog to evaluate eosinophil cell activation markers CD11b and CD69 and cytokine (IL-4, IL-5, IL-8 and IL-13) production. RESULTS Glucagon-like peptide-1 receptor is expressed on human eosinophils and neutrophils. Eosinophil, but not neutrophil, expression of GLP-1R is significantly higher in normal controls compared to allergic asthmatics. The expression of GLP-1R did not change on either eosinophils or neutrophils following allergen challenge. A GLP-1 analog significantly decreased the expression of eosinophil-surface activation markers following LPS stimulation and decreased eosinophil production of IL-4, IL-8 and IL-13, but not IL-5. CONCLUSION AND CLINICAL RELEVANCE Glucagon-like peptide-1 receptor is expressed on human eosinophils and neutrophils. A GLP-1 analog attenuates LPS-stimulated eosinophil activation. GLP-1 agonists may have additional adjunctive indications in treating persons with concomitant type 2 diabetes mellitus and asthma.
Collapse
Affiliation(s)
- P D Mitchell
- Department of Medicine, Michael G. DeGroote School of Medicine, Firestone Institute of Respiratory Health, McMaster University, Hamilton, ON, Canada
| | - B M Salter
- Department of Medicine, Michael G. DeGroote School of Medicine, Firestone Institute of Respiratory Health, McMaster University, Hamilton, ON, Canada
| | - J P Oliveria
- Department of Medicine, Michael G. DeGroote School of Medicine, Firestone Institute of Respiratory Health, McMaster University, Hamilton, ON, Canada
| | - A El-Gammal
- Department of Medicine, Michael G. DeGroote School of Medicine, Firestone Institute of Respiratory Health, McMaster University, Hamilton, ON, Canada
| | - D Tworek
- Department of Medicine, Michael G. DeGroote School of Medicine, Firestone Institute of Respiratory Health, McMaster University, Hamilton, ON, Canada
| | - S G Smith
- Department of Medicine, Michael G. DeGroote School of Medicine, Firestone Institute of Respiratory Health, McMaster University, Hamilton, ON, Canada
| | - R Sehmi
- Department of Medicine, Michael G. DeGroote School of Medicine, Firestone Institute of Respiratory Health, McMaster University, Hamilton, ON, Canada
| | - G M Gauvreau
- Department of Medicine, Michael G. DeGroote School of Medicine, Firestone Institute of Respiratory Health, McMaster University, Hamilton, ON, Canada
| | - M Butler
- Department of Medicine, University College Dublin, Dublin, Ireland
| | - P M O'Byrne
- Department of Medicine, Michael G. DeGroote School of Medicine, Firestone Institute of Respiratory Health, McMaster University, Hamilton, ON, Canada
| |
Collapse
|